Mustard oil and cardiovascular health: Why the controversy?
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or primary human trial data
PubMed 34924350 · doi:10.1016/j.jacl.2021.11.002
What was done
The authors reviewed literature and international regulatory stances regarding the cardiovascular risks and benefits of mustard oil consumption. They examined the basis for the US Food and Drug Administration (FDA) ban—derived from rodent studies showing erucic acid-induced myocardial lipidosis—compared to permissive dietary guidelines and tolerable upper limits established in the European Union, Australia, New Zealand, and India.
What was found
The abstract reports no quantitative clinical data or effect sizes. It highlights a regulatory divergence: the US FDA maintains a ban on mustard oil for cooking due to rodent data, whereas 29 countries set tolerable intake limits, and the Lipid Association of India recommends it as heart-healthy due to low saturated fat content.
Why it matters
Clarifying the safety and evidence base for mustard oil is clinically relevant for South Asian populations who face elevated cardiovascular disease risk and frequently use the oil despite conflicting global regulations.
Limits
This is a narrative review with no new human data, meta-analysis, or systematic search methodology reported in the abstract. Evidence for cardiotoxicity relies heavily on animal (rodent) models rather than human clinical outcome trials, and no specific quantitative risk thresholds are provided in the abstract.
Cited by
- supports Erucic acid has been associated with cardiac toxicities in animal studies.